Dr. Samuel So is the Lui Hac Minh Professor and Professor of Surgery. He is also the founder of the multidisciplinary liver cancer program at the Stanford Cancer Center, and the founder and executive director of the Asian Liver Center at Stanford University School of Medicine. Dr. So is a native of Hong Kong and received his surgical training at the University of Hong Kong and the University of Minnesota where he also completed his fellowship in multi-organ transplantation. His current clinical area of specialty is multidisciplinary approach in the treatment of primary liver cancer and management of chronic hepatitis B infection. He is listed among the Best Doctors in America.
Dr. So is recognized worldwide for his expertise in chronic hepatitis B and primary liver cancer prevention, research, treatment and health policy. He served as a consultant for the FDA and was a member and co-chair of the U.S. Department of Health and Human Services Office of Minority Health’s Hepatitis B Expert Panel. He was also a member of the Board of Population Health and Public Health Practices of the Institute of Medicine of the National Academies, and a committee member of the 2010 IOM report on “Hepatitis and Liver Cancer: a national strategy for the prevention and control of hepatitis B and C”, and the 2016 National Academy of Sciences, Engineering and Medicine report on “Eliminating the Public Health Problem of Hepatitis B and C in the United States. He also serves as a special adviser on viral hepatitis for the World Health Organization Western Pacific regional office. In 2010, he received the CDC and ATSDR Honor Award for mobilizing people and resources in ways that have changed global public health policies related to hepatitis B, and was recognized in 2014 by the White House for global and national leadership in the prevention and control of viral hepatitis.